Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin) in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma

NCT01124539 is registered in ClinicalTrials.gov with Arno Therapeutics as lead sponsor.

NCT NCT01124539
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01124539 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin) in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma
Lead sponsor
Arno Therapeutics
Phase
Phase 2
Overall status
Unknown status
Start date
December 31, 2009
Completion date
February 28, 2015
Enrollment
58 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

gbm, glioblastoma multiforme, gliosarcoma